[
  {
    "ts": null,
    "headline": "Fidelity Fund Q2 2025 Commentary",
    "summary": "Fidelity Investments reviews Q2 fund performance amid market volatility. See how stock selection shaped returns and explore their forward-looking strategy.",
    "url": "https://finnhub.io/api/news?id=5df73e5d2e5214870ef208a2b29b34e9e97fe3be2676717d08eed9859d5472c9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753564500,
      "headline": "Fidelity Fund Q2 2025 Commentary",
      "id": 136098255,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165312975/image_2165312975.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments reviews Q2 fund performance amid market volatility. See how stock selection shaped returns and explore their forward-looking strategy.",
      "url": "https://finnhub.io/api/news?id=5df73e5d2e5214870ef208a2b29b34e9e97fe3be2676717d08eed9859d5472c9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment",
    "summary": "Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's...",
    "url": "https://finnhub.io/api/news?id=2bce6259adaaa1c80786f05920c0a8100e90336e222e78dfccf4d5ea19eb10e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753550068,
      "headline": "Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment",
      "id": 136101660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's...",
      "url": "https://finnhub.io/api/news?id=2bce6259adaaa1c80786f05920c0a8100e90336e222e78dfccf4d5ea19eb10e4"
    }
  },
  {
    "ts": null,
    "headline": "Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might",
    "summary": "The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well.",
    "url": "https://finnhub.io/api/news?id=1d21a2ec8f8c1a4b5cec0eca40ed0c021310f3f350142281ad1c6d0e13df3dea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753535760,
      "headline": "Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might",
      "id": 136101661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well.",
      "url": "https://finnhub.io/api/news?id=1d21a2ec8f8c1a4b5cec0eca40ed0c021310f3f350142281ad1c6d0e13df3dea"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Blue Chip Growth ETF Q2 2025 Commentary",
    "summary": "Fidelity Investments reports a 20%+ Q2 surge for its Blue Chip Growth ETF, led by AI winners like Nvidia. Explore how smart picks beat the benchmark.",
    "url": "https://finnhub.io/api/news?id=b49805578d8bca4fa39284a5c605570385f8776320f7ea4af94597a308172903",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753533900,
      "headline": "Fidelity Blue Chip Growth ETF Q2 2025 Commentary",
      "id": 136095746,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201431048/image_2201431048.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments reports a 20%+ Q2 surge for its Blue Chip Growth ETF, led by AI winners like Nvidia. Explore how smart picks beat the benchmark.",
      "url": "https://finnhub.io/api/news?id=b49805578d8bca4fa39284a5c605570385f8776320f7ea4af94597a308172903"
    }
  }
]